EMA
withdrawal
· 2018-08-09
EMA Withdrawn: Numient (levodopa;carbidopa) — Amneal Pharma Europe Ltd
Summary
Numient (levodopa; carbidopa) has been withdrawn from the European market by Amneal Pharma Europe Ltd for Parkinson's disease.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Withdrawn. Therapeutic area: Parkinson Disease. MAH: Amneal Pharma Europe Ltd. Decision date: 03/08/2018